Targeting kinome reprogramming in ESR1 fusion-driven breast cancer

被引：0
|
作者：
Gou, Xuxu
Kim, Beom-Jun
Anurag, Meenakshi
Lei, Jonathan T.
Young, Meggie N.
Holt, Matthew V.
Fandino, Diana
Vollert, Craig T.
Singh, Purba
Alzubi, Mohammad A.
Malovannaya, Anna
Dobrolecki, Lacey E.
Lewis, Michael T.
Li, Shunqiang
Ellis, Matthew J.
Foulds, Charles E.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5011
引用
收藏
页数：3
相关论文
共 50 条
  • [21] ESR1 mutations: a new biomarker in breast cancer
    Carausu, Marcela
    Bidard, Francois-Clement
    Callens, Celine
    Melaabi, Samia
    Jeannot, Emmanuelle
    Pierga, Jean-Yves
    Cabel, Luc
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2019, 19 (07) : 599 - 611
  • [22] Functional characterization of ESR1 fusions in breast cancer
    Gou, Xuxu
    Lei, Jonathan T.
    Seker, Sinem
    Kim, Beom-Jun
    Rehman, Saif
    Lee, Adrian V.
    Robinson, Dan R.
    Ellis, Matthew J.
    CANCER RESEARCH, 2020, 80 (04)
  • [23] ESR1 mutations in metachronous contralateral breast cancer
    Velthuisen, D.
    Akkers, R.
    Menke-Pluijmers, M.
    Kitzen, J.
    Westenend, P.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S124 - S124
  • [24] ESR1 amplification in breast cancer: controversy resolved?
    Albertson, Donna G.
    JOURNAL OF PATHOLOGY, 2012, 227 (01): : 1 - 3
  • [25] Isorhamnetin inhibits progression of ovarian cancer by targeting ESR1
    Wang, Manman
    Xu, Zhengtan
    Cai, Qi
    Deng, Yanmei
    Shi, Weiqiao
    Zhou, Hongyu
    Wang, Dajiang
    Li, Jian
    ANNALS OF TRANSLATIONAL MEDICINE, 2022,
  • [26] Targeting ESR1 mutation-induced transcriptional addiction in breast cancer with BET inhibition
    Udden, Sm N.
    Wang, Qian
    Kumar, Sunil
    Malladi, Venkat S.
    Wu, Shwu-Yuan
    Wei, Shuguang
    Posner, Bruce A.
    Geboers, Sophie
    Williams, Noelle S.
    Liu, Yulun
    Sharma, Jayesh K.
    Mani, Ram S.
    Malladi, Srinivas
    Parra, Karla
    Hofstad, Mia
    Raj, Ganesh, V
    Larios, Jose M.
    Jagsi, Reshma
    Wicha, Max S.
    Park, Ben Ho
    Gupta, Gaorav P.
    Chinnaiyan, Arul M.
    Chiang, Cheng-Ming
    Alluri, Prasanna G.
    JCI INSIGHT, 2022, 7 (17)
  • [27] Targeting wild type and ESR1 mutations as neoantigens in hormone receptor positive breast cancer
    Gautam, Namrata
    Albert, Gabriella
    Synder, Colin
    Czerniecki, Brian
    CANCER RESEARCH, 2024, 84 (03)
  • [28] Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
    Hartmaier, R. J.
    Trabucco, S. E.
    Priedigkeit, N.
    Chung, J. H.
    Parachoniak, C. A.
    Vanden Borre, P.
    Morley, S.
    Rosenzweig, M.
    Gay, L. M.
    Goldberg, M. E.
    Suh, J.
    Ali, S. M.
    Ross, J.
    Leyland-Jones, B.
    Young, B.
    Williams, C.
    Park, B.
    Tsai, M.
    Haley, B.
    Peguero, J.
    Callahan, R. D.
    Sachelarie, I.
    Cho, J.
    Atkinson, J. M.
    Bahreini, A.
    Nagle, A. M.
    Puhalla, S. L.
    Watters, R. J.
    Erdogan-Yildirim, Z.
    Cao, L.
    Oesterreich, S.
    Mathew, A.
    Lucas, P. C.
    Davidson, N. E.
    Brufsky, A. M.
    Frampton, G. M.
    Stephens, P. J.
    Chmielecki, J.
    Lee, A. V.
    ANNALS OF ONCOLOGY, 2018, 29 (04) : 872 - 880
  • [29] RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond
    Wu, Jie
    Subbiah, Vivek
    CANCER RESEARCH, 2023, 83 (19) : 3159 - 3161
  • [30] ESR1 mutations, ESR1 fusions and co-occurring alterations assessed in breast cancer tumors
    Tan, A.
    Feldman, R.
    Pohlmann, P.
    Lynce, F.
    Swain, S.
    Nunes, M. R.
    Gatalica, Z.
    Ghazalpour, A.
    Swensen, J.
    Vidal, G.
    Obeid, E.
    Vacirca, J.
    Isaacs, C.
    Schwartzberg, L.
    CANCER RESEARCH, 2017, 77
12345